Three economists explore the viability of a UN-backed one-stop licensing ‘hub’ for making essential, often life-saving biotherapeutics and vaccines both affordable and more widely available.
Articles on Generic drug pricing
Displaying all articles
The benefit of an injectable product is that it avoids the adherence issues related to taking a pill daily.
A new law will let Medicare bargain for the first time. But a health policy scholar explains why it’s unlikely to make much of a difference in how much seniors – or anyone else – pays for their meds.
Biologics, therapies made inside or of living cells, are a growing share of pharmaceutical sales. But the cost of these miracle treatments makes them unaffordable for many. New FDA guidance may help.
Small-batch brewers are starting to tinker with biologic drugs to meet their own medical needs. A side effect of their success would be a disruption to how big pharma makes and distributes drugs.
The rising costs of generic drugs have led to outcries. In a search for solutions, four hospital systems are proposing to make drugs on their own. Could their idea work?
Top contributors
-
Postdoctoral Researcher in Chemical and Biological Engineering, Colorado State University
-
Professor of Management, MIT Sloan School of Management
-
Professor, Abell Chair in Synthetic Biology, Colorado State University
-
Professor of Law, Georgia State University
-
Associate Professor of Public Health, The Ohio State University
-
Senior Researcher, University of the Witwatersrand
-
Research associate professor in Global Health, Boston University
-
Professor of Economics, Université Clermont Auvergne (UCA)
-
Professor, Université de Lille
-
Professor of industrial economics, EM Lyon Business School